Nu-Med Plus (NUMD) Cash from Financing Activities (2012 - 2025)

Nu-Med Plus (NUMD) reported Cash from Financing Activities of $33767.0 for Q4 2025, up 12.56% sequentially from $30000.0 in Q1 2021.

Nu-Med Plus (NUMD) Cash from Financing Activities (2012 - 2025) Analysis & Trends

Nu-Med Plus (NUMD) has 11 years of Cash from Financing Activities data on file, last reported at $33767.0 in Q4 2025.

For the quarter ending Q4 2025, Cash from Financing Activities changed N/A year-over-year to $33767.0; the trailing twelve-month figure through Dec 2025 stood at $33767.0 (changed N/A YoY), and the FY2025 full-year result was $46267.0, changed N/A from the prior year.
Cash from Financing Activities improved to $33767.0 in Q4 2025, from $30000.0 in the prior quarter.
In the past five years, Cash from Financing Activities ranged from a high of $33767.0 in Q4 2025 to a low of $30000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Financing Activities (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	17.31 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-1.51 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-888.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-260.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-451.20 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-25.00 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-26.93 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	21.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Nu-Med Plus	1.67 Mn	1.67 Mn	-	33,767.00

Download Data